12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mitizax: Phase III data

Top-line data from the double-blind, European Phase III MITRA (MT-04) trial in 834 patients with house dust mite-induced allergic asthma showed that once-daily HDM AIT for up to 18 months met the primary endpoint of reducing the risk of moderate to severe asthma exacerbations vs. placebo (p<0.05). HDM AIT was well tolerated. Patients received once-daily placebo or 1 of 2 doses of HDM AIT. All patients received inhaled corticosteroids (ICS) until the last part of...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >